Literature DB >> 28808903

Clinical outcomes of aortic repair in young adult patients with ACTA2 mutations.

Yoshimasa Seike1, Kenji Minatoya2, Hiroaki Sasaki1, Hiroshi Tanaka1, Tatsuya Itonaga1, Yosuke Inoue1, Hiroko Morisaki3, Takayuki Morisaki3, Hatsue Ishibashi-Ueda4, Junjiro Kobayashi1.   

Abstract

OBJECTIVES: Actin, alpha-2, smooth muscle, aorta (ACTA2) mutations are one of the major causes of familial thoracic aortic aneurysms and dissections. The aim of this study was to review our clinical results of young adult patients with aortic disease caused by ACTA2 mutations.
METHODS: We reviewed the medical records of 251 patients (<50 years old) who underwent surgery for thoracic aortic diseases between 2004 and 2014. Among them, nine patients (3.5%) had ACTA2 mutations. Their average age was 35 years (range 22-47) and two patients (22.2%) were males. No patients fulfilled the diagnostic criteria for Marfan syndrome. Preoperative diagnoses included annulo-aortic ectasia (n = 2), localized dissection of the sinus of Valsalva (n = 2), acute type B aortic dissection (n = 1), and chronic type B (n = 4). Eight patients (88.9%) had hypertension.
RESULTS: A thoracoabdominal aortic replacement was required in three patients who had descending replacement for residual chronic type B aortic dissection. A patient who had thoracic endovascular aortic repair for complicated acute type B aortic dissection showed no aortic dilatation for 7 years after TEVAR. Histological results revealed cystic medial necrosis (CMN) in most cases (7/8; 87.5%).
CONCLUSION: Surgical outcomes for patients with ACTA2 mutations were satisfactory. CMN was a major histological finding and family history of aortic event was detected in only half of the patients with ACTA2 mutations. Despite no characteristic physical findings besides hypertension, connective tissue disease including ACTA2 mutations should be considered for aortic dissection in young adult patients.

Entities:  

Keywords:  ACTA2; Cystic medial necrosis; Familial thoracic aortic aneurysms and dissections; Hereditary aortic diseases; Hypertension

Mesh:

Substances:

Year:  2017        PMID: 28808903     DOI: 10.1007/s11748-017-0810-0

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  17 in total

1.  Long-term prognosis of type A aortic dissection in non-Marfan patients with histologic pattern of cystic medial necrosis.

Authors:  Evaldas Girdauskas; Thomas Kuntze; Michael A Borger; Torsten Doenst; Michael Mochalski; Thomas Walther; Volkmar Falk; Friedrich W Mohr
Journal:  Ann Thorac Surg       Date:  2008-03       Impact factor: 4.330

2.  Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene.

Authors:  H C Dietz; G R Cutting; R E Pyeritz; C L Maslen; L Y Sakai; G M Corson; E G Puffenberger; A Hamosh; E J Nanthakumar; S M Curristin
Journal:  Nature       Date:  1991-07-25       Impact factor: 49.962

3.  Aortic Disease Presentation and Outcome Associated With ACTA2 Mutations.

Authors:  Ellen S Regalado; Dong-chuan Guo; Siddharth Prakash; Tracy A Bensend; Kelly Flynn; Anthony Estrera; Hazim Safi; David Liang; James Hyland; Anne Child; Gavin Arno; Catherine Boileau; Guillaume Jondeau; Alan Braverman; Rocio Moran; Takayuki Morisaki; Hiroko Morisaki; Reed Pyeritz; Joseph Coselli; Scott LeMaire; Dianna M Milewicz
Journal:  Circ Cardiovasc Genet       Date:  2015-03-10

4.  Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders.

Authors:  David Attias; Chantal Stheneur; Carine Roy; Gwenaëlle Collod-Béroud; Delphine Detaint; Laurence Faivre; Marie-Ange Delrue; Laurence Cohen; Christine Francannet; Christophe Béroud; Mireille Claustres; Franck Iserin; Philippe Khau Van Kien; Didier Lacombe; Martine Le Merrer; Stanislas Lyonnet; Sylvie Odent; Henri Plauchu; Marlène Rio; Annick Rossi; Daniel Sidi; Philippe Gabriel Steg; Philippe Ravaud; Catherine Boileau; Guillaume Jondeau
Journal:  Circulation       Date:  2009-12-07       Impact factor: 29.690

Review 5.  Epidemiology of thoracic aortic dissection.

Authors:  Scott A LeMaire; Ludivine Russell
Journal:  Nat Rev Cardiol       Date:  2010-12-21       Impact factor: 32.419

6.  Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome.

Authors:  T E Bunton; N J Biery; L Myers; B Gayraud; F Ramirez; H C Dietz
Journal:  Circ Res       Date:  2001-01-19       Impact factor: 17.367

7.  Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome.

Authors:  Romy Franken; Alexander W den Hartog; Teodora Radonic; Dimitra Micha; Alessandra Maugeri; Fleur S van Dijk; Hanne E Meijers-Heijboer; Janneke Timmermans; Arthur J Scholte; Maarten P van den Berg; Maarten Groenink; Barbara J M Mulder; Aeilko H Zwinderman; Vivian de Waard; Gerard Pals
Journal:  Circ Cardiovasc Genet       Date:  2015-01-22

8.  Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.

Authors:  Benjamin S Brooke; Jennifer P Habashi; Daniel P Judge; Nishant Patel; Bart Loeys; Harry C Dietz
Journal:  N Engl J Med       Date:  2008-06-26       Impact factor: 91.245

9.  Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991.

Authors:  V L Burt; J A Cutler; M Higgins; M J Horan; D Labarthe; P Whelton; C Brown; E J Roccella
Journal:  Hypertension       Date:  1995-07       Impact factor: 10.190

10.  Acute aortic dissections with pregnancy in women with ACTA2 mutations.

Authors:  Ellen S Regalado; Dong-chuan Guo; Anthony L Estrera; L Maximilian Buja; Dianna M Milewicz
Journal:  Am J Med Genet A       Date:  2013-11-15       Impact factor: 2.802

View more
  1 in total

1.  Surgical Outcome and Histological Differences between Individuals with TGFBR1 and TGFBR2 Mutations in Loeys-Dietz Syndrome.

Authors:  Yoshimasa Seike; Hitoshi Matsuda; Hatsue Ishibashi-Ueda; Hiroko Morisaki; Takayuki Morisaki; Kenji Minatoya; Hitoshi Ogino
Journal:  Ann Thorac Cardiovasc Surg       Date:  2021-01-06       Impact factor: 1.520

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.